REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers
At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted radiotherapeutic drug candidate. Designed to treat some of the most aggressive and underserved cancers, REYOBIQ™ is being developed for:
- Recurrent Glioblastoma (GBM)
- Leptomeningeal Metastases (LM)
- Pediatric Brain Cancers (PBC)
We are proud to announce that the U.S. Food and Drug Administration (FDA) has recognized the potential of REYOBIQ™ with several important designations, including:
✅ Orphan Drug Designation (ODD) for glioblastoma, leptomeningeal metastases in breast cancer and lung cancer patients
✅ Fast Track Designation for both glioblastoma and leptomeningeal metastases
These designations highlight the urgency and promise of REYOBIQ™ in addressing cancers with high unmet medical need and limited treatment options.
Our mission is to deliver safe, effective, and targeted cancer therapies using our proprietary rhenium-based radiotherapeutic platform, which allows for precise tumor targeting and minimal impact to healthy tissue.
🔬 Learn more about REYOBIQ™ and our clinical programs, including ReSPECT-GBM and ReSPECT-LM, on our website:
👉 https://plustherapeutics.com/our-platform/
#REYOBIQ #Rhenium186Obisbemeda #Glioblastoma #GBM #LeptomeningealMetastases #LM #PediatricBrainCancer #HighGradeGlioma #Ependymoma #FDA #FastTrackDesignation #OrphanDrugDesignation #ReSPECTGBM #ReSPECTLM #Radiotherapeutics #TargetedTherapies #PlusTherapeutics
Recent Comments